ALKERMES PLC

Alkermes insider sale by SVP Todd: a routine Rule 10b‑5 plan trade, no distress signal, but watch upcoming Phase III data and insider activity for potential volatility.

Alkermes CEO Jackson Blair Curtis buys shares and receives a 10‑year option grant, signaling confidence amid insider sales and a high‑PE biotech outlook.

Alkermes insider sale: how a June 2,000‑share divestment reflects broader CNS pipeline strength, digital trial innovation, and value‑based reimbursement prospects.

Alkermes insider sale: EVP Gaffin’s 2,034 share sale under a Rule 10b‑5 plan shows no price impact, highlighting disciplined trading amid a strong CNS drug pipeline.

Alkermes insider trading insights: Craig Hopkinson’s recent 5,000‑share purchase shows steady confidence and a disciplined Rule 10b‑5 strategy—what it means for investors.

Alkermes execs receive big equity awards—CFO gets 97k shares—showing a strategy to lock talent, align incentives, and support future R&D and valuation upside.

Alkermes insider buying signals confidence in its CNS pipeline, with ALKS‑3831 & ALKS‑4800 poised for regulatory success and improved treatment of addiction and schizophrenia.

Alkermes insider trade: EVP Gaffin buys shares slightly below market, signalling confidence in the company’s CNS and upcoming sleep‑medicine expansion. Click to learn how the Avadel acquisition may boost value and investor prospects.

Alkermes insider trades reveal disciplined finance‑leadership buying/selling, offering investors insight into corporate confidence, regulatory compliance and growth prospects after the Avadel acquisition.

Alkermes insider buys 5,000 shares amid FDA‑boosted alixorexton; learn how this 10‑year plan trade signals future upside for CNS drug developers.